146 related articles for article (PubMed ID: 33731590)
1. Serum anandamide level as a potential indicator for nonalcoholic fatty liver disease severity.
Ramadan A; Khalaf AR; El Ray A; Saad Y
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e363-e367. PubMed ID: 33731590
[TBL] [Abstract][Full Text] [Related]
2. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines.
Jamali R; Arj A; Razavizade M; Aarabi MH
Medicine (Baltimore); 2016 Feb; 95(5):e2630. PubMed ID: 26844476
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
5. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
6. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
[TBL] [Abstract][Full Text] [Related]
7. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
8. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
[TBL] [Abstract][Full Text] [Related]
9. Serum Resistin Level and Its Receptor Gene Expression in Liver Biopsy as Predictors for the Severity of Nonalcoholic Fatty Liver Disease.
Hegazy M; Abo-Elfadl S; Mostafa A; Ibrahim M; Rashed L; Salman A
Euroasian J Hepatogastroenterol; 2014; 4(2):59-62. PubMed ID: 29699348
[TBL] [Abstract][Full Text] [Related]
10. Radiologic evaluation of nonalcoholic fatty liver disease.
Lee SS; Park SH
World J Gastroenterol; 2014 Jun; 20(23):7392-402. PubMed ID: 24966609
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
[TBL] [Abstract][Full Text] [Related]
12. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
[TBL] [Abstract][Full Text] [Related]
13. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
14. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Sumida Y; Nakajima A; Itoh Y
World J Gastroenterol; 2014 Jan; 20(2):475-85. PubMed ID: 24574716
[TBL] [Abstract][Full Text] [Related]
15. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
[TBL] [Abstract][Full Text] [Related]
16. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
17. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
[TBL] [Abstract][Full Text] [Related]
18. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
[TBL] [Abstract][Full Text] [Related]
19. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease.
Zelber-Sagi S; Azar S; Nemirovski A; Webb M; Halpern Z; Shibolet O; Tam J
Obesity (Silver Spring); 2017 Jan; 25(1):94-101. PubMed ID: 27863097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
